Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

WITHDRAWN

Identifier: CI-TRIAL-00069926
Entity page: /trial/NCT05295589 ↗
Edges: 14

Neighbours: 9 cancers5 drugs
Drawn: 14 of 14 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy condition of …CONDITION_OFderived9 of 9
← condition of	Fallopian Tube Endometrioid Adenocarcinoma registry condition “Recurrent Fallopian Tube Endometrioid Adenocarcinoma” mapped CURATED_BROADER	—	—	Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
← condition of	Fallopian Tube High Grade Serous Adenocarcinoma

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy intervention of …INTERVENTION_OFderived5 of 5
← intervention of	Copanlisibsmall molecule registry intervention “Copanlisib Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Doxorubicinsmall molecule registry intervention “Pegylated Liposomal Doxorubicin Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Olaparibsmall molecule registry intervention “Olaparib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Paclitaxelsmall molecule registry intervention “Paclitaxel” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Topotecansmall molecule registry intervention “Topotecan Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy intervention of …INTERVENTION_OFderived5 of 5

← intervention of

Copanlisibsmall molecule

registry intervention “Copanlisib Hydrochloride” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Doxorubicinsmall molecule

registry intervention “Pegylated Liposomal Doxorubicin Hydrochloride” (DRUG) mapped ALIAS

—